For episode 37, we connect with David Bearss, President and CEO of Halia Therapeutics. Learn more about the connection between chronic inflammation and disease, and how Halia is using their novel therapies to treat both inflammatory disorders and neurological diseases.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.